Corporate Snapshot: Kede Numerical Control and Peer Performance
Kede Numerical Control (688305.SS) finished the trading session on Friday, 23 October 2026, unchanged at 0 % from the previous close. The share price settled at CNY 46.38 on the Shanghai Stock Exchange, a figure that reflects a steady, if flat, trading environment for the company this morning.
Market Overview
- Shares Outstanding: 133 million
- Market Capitalisation: CNY 6 billion
- Turnover (last 24 h): Approximately CNY 80.6 million
- Price‑to‑Earnings (P/E): Not disclosed in the brief, but the company’s valuation appears moderate given its flat trading day.
The stock’s performance over the past month has deteriorated, with a 22.34 % decline from the end‑of‑month level. In a broader context, the 200‑day simple moving average sits at CNY 59.67, suggesting that the current price of CNY 46.38 is below the medium‑term trend line. The peak price in the last 52 weeks was CNY 80.69 on 7 February 2026, while the 52‑week low was CNY 43.80 on 19 October 2026, indicating that the current trading level is closer to the lower end of its recent range.
Peer Comparison
The following table summarises how related stocks performed over the same 24‑hour window:
| Symbol | Current Price | Market Cap | Recent Performance |
|---|---|---|---|
| China Boya Bio‑p (300294.SZ) | CNY 14.01 | CNY 7.1 bn | Flat 0 % |
| Hengyi Petrochemical (000703.SZ) | CNY 12.62 | CNY 7.7 bn | Flat 0 % |
| Beijing Geekplus Technology (2590.HK) | HKD 6.5 | HKD 8.4 bn | Down –5.87 % |
| Jiangsu Yanghe Distillery (002304.SZ) | CNY 37.2 | CNY 7.7 bn | Flat 0 % |
| Amoy Diagnostics (300685.SZ) | CNY 19.54 | CNY 7.2 bn | Flat 0 % |
The peer group displays a mix of stability and mild decline. Beijing Geekplus Technology’s drop of 5.87 % stands out as the only negative movement in this cohort, whereas the others held steady.
Amoy Diagnostics Update
Amoy Diagnostics, which also trades flat, released its third‑quarter results for 2026. Revenue growth was modest, yet net profit slipped slightly. Nonetheless, operating cash flow increased, signalling improved cash generation. After adjusting for foreign‑exchange effects, earnings per share and net profit exhibited a positive trend, underscoring the company’s resilience in core operations. A share‑transfer agreement with a major investor was announced, indicating ongoing adjustments to the ownership structure. This development suggests that while Amoy Diagnostics faces some pressure from currency movements, it remains focused on maintaining a robust biomedical product portfolio.
Conclusion
Kede Numerical Control’s flat performance today reflects a broader period of price consolidation. With a market cap of CNY 6 billion and a current price well below the 200‑day moving average, investors may view the share as a potential buying opportunity should the trend reverse. The peer group’s stability, coupled with Beijing Geekplus Technology’s slight decline, paints a picture of a sector largely resistant to short‑term volatility but sensitive to broader market swings. As Kede Numerical Control navigates its current valuation landscape, stakeholders will be watching for any shifts that might signal a return to upward momentum.
